Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%

MT Newswires Live

2025/05/29

Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.

The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.

Shares rose 6% in afternoon trade Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539282712"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539282712\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539282712?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 11:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539282712","market":"sh","top_or_hot":-1,"title":"Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.</p><p>The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.</p><p>Shares rose 6% in afternoon trade Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNoxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-29 11:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.</p><p>The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.</p><p>Shares rose 6% in afternoon trade Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2539282712","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539282712","pubTimestamp":1748490466,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Noxopharm  secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.Shares rose 6% in afternoon trade Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK7508":"医药生物股","BK7067":"生物科技","NOX.AU":"NOXOPHARM LTD"},"translate_title":"Noxopharm获得炎症性疾病候选药物首次人体试验的伦理批准；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOX.AU":0.9},"content_text":"Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.Shares rose 6% in afternoon trade Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}